ELTX — Elicio Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1601485 ·
Last close
$1.84
Market Cap
$48.36M
52W High
$16.00
52W Low
$1.71
ADV30
349,550
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -10,429,000 | -8,217,000 | 31,330,000 | 23,480,000 | 23,393,000 |
| Mar 2026 | 0 | — | -10,602,000 | -11,823,000 | 22,689,000 | 14,948,000 | 24,126,000 |
| Dec 2025 | 0 | — | -8,842,000 | -7,718,000 | 25,862,000 | 18,563,000 | 24,226,000 |
| Sep 2025 | 0 | — | -8,045,000 | -10,083,000 | 28,284,000 | 20,611,000 | 24,468,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-38,478,000
Investing CF
$-16,000
Financing CF
$34,394,000
CapEx
$-45,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.78
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-245,495,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-38,821,000
Pretax Income TTM
$-40,185,000
Interest Exp TTM
$1,364,000
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -37,299,000 | -39,571,000 | 25,862,000 | 24,226,000 | 1,636,000 | -36,952,000 |
| Dec 2024 | 0 | -44,986,000 | -51,898,000 | 28,178,000 | 39,490,000 | -11,312,000 | -37,068,000 |
| Dec 2023 | 0 | -35,745,000 | -35,195,000 | 27,146,000 | 15,773,000 | 11,373,000 | -32,694,000 |
| Dec 2022 | 0 | -23,733,000 | -28,208,000 | 22,664,000 | 124,809,000 | -102,145,000 | -22,179,000 |
TTM Snapshot
Revenues TTM
$5,433,000
NetIncome TTM
$-47,903,000
OpCashFlow TTM
$0
Assets (Latest)
$25,862,000
Forward EPS
$-2.17
Max Pain — expiry 2026-11-20
max pain strike: $2.50 · spot: $1.85 · call oi: 214 · put oi: 1,909
Expected Move to 2026-11-20:
±$1.18
(63.51%) —
implied range
$0.68 –
$3.03
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LITS | Lite Strategy, Inc. | $49.00M | $1.44 | — |
| HOWL | Werewolf Therapeutics, Inc. | $46.66M | $0.96 | — |
| DWTX | Dogwood Therapeutics, Inc. | $46.23M | $1.36 | — |
| PDSB | PDS Biotechnology Corp | $44.61M | $0.80 | — |
| GRCE | Grace Therapeutics, Inc. | $44.60M | $2.12 | — |
News headlines (Yahoo Finance, 1h cache)
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
2026-09-24 12:00 · Yahoo
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-31 12:00 · Yahoo
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
2026-08-24 12:00 · Yahoo
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
2026-07-02 04:25 · Yahoo
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
2026-06-29 12:00 · Yahoo
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
2026-06-17 12:00 · Yahoo
Top Midday Decliners
2026-06-15 18:01 · Yahoo
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
2026-06-15 11:00 · Yahoo
Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology
2026-06-01 12:00 · Yahoo
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-11 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.